Literature DB >> 24019702

In-vitro activity of synercid and related drugs against Streptococcus oralis isolated from septicaemia and endocarditis cases.

A M Rafay1.   

Abstract

OBJECTIVE: The increase in resistance to gram positive organisms and seriousness of infective endocarditis, makes it necessary to look for an alternate treatment.
METHOD: In-vitro activity of synercid was compared with penicillin, amoxycillin, teicoplanin, vancomycin, clindamycin and erythromycin. RESULT: Synercid showed minimum inhibitory concentrations (MIC) within the narrow range of 0.06 - 0.5 mg/l. MIC50 and mode values were both 0.25 mg/l. There was just two-fold difference between the MIC50 (0.25 mg/l) and the MIC90, (0.5 mg/l). Although the MICs of synercid for S. oralis were relatively high compared to penicillin, clindamycin, erythromycin and teicoplanin, the in-vitro bactericidal activity of synercid was much greater. Synercid MBC values were < 4 mg/l for most of the isolates, except for one of 16 mg/l and the other >64 mg/l. Killing curve was performed on six isolates of S. oralis from infective endocarditis, two from septicaemia patients and two from the oral flora of normal individuals.
CONCLUSION: Synercid showed superior bactericidal activity when compared to penicillin and vancomycin against all ten isolates of S. oralis tested. Synercid was bactericidal (99.9% kill) against all ten isolates of S. oralis within six hours of contact.

Entities:  

Keywords:  amoxycillin; clindamycin; erythromycin; penicillin; streptococcus oralis; synercid; teicoplanin; vancomycin

Year:  2000        PMID: 24019702      PMCID: PMC3174699     

Source DB:  PubMed          Journal:  J Sci Res Med Sci        ISSN: 1029-4066


  20 in total

1.  In-vitro activity of RP 59500, a semisynthetic streptogramin, against staphylococci and streptococci.

Authors:  J C Pechère
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

2.  The estimation of the bactericidal power of the blood.

Authors:  A A Miles; S S Misra; J O Irwin
Journal:  J Hyg (Lond)       Date:  1938-11

Review 3.  Coagulase-negative staphylococci. Epidemiology, evaluation, and therapy.

Authors:  D A Nafziger; R P Wenzel
Journal:  Infect Dis Clin North Am       Date:  1989-12       Impact factor: 5.982

4.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

5.  The microbiology and pathogenesis of infective endocarditis.

Authors:  R Bayliss; C Clarke; C M Oakley; W Somerville; A G Whitfield; S E Young
Journal:  Br Heart J       Date:  1983-12

6.  Identity of viridans streptococci isolated from cases of infective endocarditis.

Authors:  C W Douglas; J Heath; K K Hampton; F E Preston
Journal:  J Med Microbiol       Date:  1993-09       Impact factor: 2.472

7.  Streptococci and aerococci associated with systemic infection in man.

Authors:  M T Parker; L C Ball
Journal:  J Med Microbiol       Date:  1976-08       Impact factor: 2.472

8.  In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

9.  A scheme for the identification of viridans streptococci.

Authors:  D Beighton; J M Hardie; R A Whiley
Journal:  J Med Microbiol       Date:  1991-12       Impact factor: 2.472

10.  Antimicrobial activity against Staphylococcus aureus of semisynthetic injectable streptogramins: RP 59500 and related compounds.

Authors:  J C Barrière; D H Bouanchaud; J M Paris; O Rolin; N V Harris; C Smith
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

View more
  1 in total

1.  Characterization of high-level daptomycin resistance in Viridans group Streptococci developed upon in vitro exposure to daptomycin.

Authors:  Ronda L Akins; Bradley D Katz; Catherine Monahan; Dylan Alexander
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.